Register Login

Absci Corporation (ABSI)

(75% Positive) Absci Corporation (ABSI) Announces Enrollment Update for included Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:57 p.m.

    📋 Absci Corporation (ABSI) - Clinical Trial Update

    Filing Date: 2026-01-14

    Accepted: 2026-01-14 17:27:05

    Event Type: Clinical Trial Update

    Event Details:

    Absci Corporation (ABSI) Announces Clinical Trial Update Absci Corporation (ABSI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: included
    • Clinical Stage: clinical trial
      • expected in 2H2026
      • Expected initiation o 2H 2026

    🔬 Clinical Development Pipeline (Absci Corporation):

    Product Type Development Stage Therapeutic Area Source
    Comparison of 2 cooling procedures PROCEDURE Phase PHASE4 Hypothermia ClinicalTrials.gov
    Adverse Reactions of Gammagard subdermally at Week 36 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Gammagard subdermally at Week 24 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Gammagard subdermally at Week 12 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Gammagard subcutaneously at Week 36 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Gammagard subcutaneously at Week 24 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Gammagard subcutaneously at Week 12 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subdermally at Week 36 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subdermally at Week 24 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subdermally at Week 12 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subcutaneously at Week 36 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subcutaneously at Week 24 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Efficacy of Gammagard subcutaneously at Week 12 DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Gadolinium For lower back DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Gadolinium For abdomen DRUG Phase PHASE1 Primary Immunodeficiency ClinicalTrials.gov
    Adverse Reactions of Botox subdermally DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Adverse Reactions of Botox intramuscularly DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox subdermally at Week 30 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox subdermally at Week 24 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox subdermally at Week 18 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox subdermally at Week 12 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox subdermally at Week 6 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox intramuscularly at Week 30 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox intramuscularly at Week 24, DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox intramuscularly at Week 18 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox intramuscularly at Week 12 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Efficacy of Botox intramuscularly at Week 6 DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Gadolinium DRUG Phase PHASE1 Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. ClinicalTrials.gov
    Adverse Reactions of Enbrel subdermally at Week 36 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Adverse Reactions of Enbrel subcutaneously DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subdermally at Week 36 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subdermally at Week 24 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subdermally at Week 12 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subcutaneously at Week 36 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subcutaneously at Week 24 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    PASI 75 n(%) subcutaneously at Week 12 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subdermally at Week 36 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subdermally at Week 24 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subdermally at Week 12 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subcutaneously at Week 36 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subcutaneously at Week 24 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov
    Efficacy of Enbrel subcutaneously at Week 12 DRUG Phase PHASE1 Plaque Psoriasis. ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Absci Corporation
    • Ticker Symbol: ABSI

Search

News categories